PRWeb.com Press Release Feed - PRWeb Press Release Account Feed

Respect Your Universe, Inc. Partners with Invoke Media, a Brand and Product Marketing Company

Thu, 30 Jun 2011 13:00:00 GMT

Respect Your Universe, Inc. partners with invoke media, a brand and product marketing company.

(PRWeb June 30, 2011)

Read the full story at http://www.prweb.com/releases/2011/6/prweb8613007.htm

Respect Your Universe Appoints Steve Eklund as Chief Financial Officer

Mon, 20 Jun 2011 12:00:00 GMT

Respect Your Universe, Inc. (OTCBB: RYUN) is pleased to announce it has appointed Steven H. Eklund as its Chief Financial Officer effective June 17th, 2011. His responsibilities will include Finance, Administration and Strategic Planning for the company.

(PRWeb June 20, 2011)

Read the full story at http://www.prweb.com/releases/2011/6/prweb8584984.htm

Respect Your Universe, Inc. Appoints Christopher Martens as Chief Executive Officer

Mon, 06 Jun 2011 17:00:00 GMT

Respect Your Universe, Inc. (OTCBB: RYUN; the “Company”) is pleased to announce it has appointed Christopher Martens as Chief Executive Officer of the Company effective June 7th, 2011. Former Chief Executive Officer Kristian Andresen will continue to serve as Chairman of the Board for the Company.

(PRWeb June 06, 2011)

Read the full story at http://www.prweb.com/releases/2011/6/prweb8533933.htm

Respect Your Universe Appoints John Wood as President

Thu, 02 Jun 2011 12:30:00 GMT

Respect Your Universe, Inc. (OTCBB: RYUN; the “Company”) is pleased to announce it has appointed John Wood as President of the Company, effective June 2, 2011. Former President Kristian Andresen will continue to serve as Chief Executive Officer.

(PRWeb June 02, 2011)

Read the full story at http://www.prweb.com/releases/2011/6/prweb8512077.htm

TooNiceStocks Initiates Coverage on Aeterna Zentaris Inc. - Smallcap Investors Eye Long Term Potential

Thu, 26 May 2011 12:00:00 GMT

Aeterna Zentaris is a late stage oncology drug development company with numerous upcoming milestones and catalyst. Their pipeline includes Perifosine, Solorel, and AEZS-108, each with multiple indications. Perifosine has a Special Protocol Assessment (SPA) Phase III X-PECT trial in metastatic colorectal cancer and is expected to be completed in the second half of 2011. With ASCO coming in June TooNiceStocks anticipates AEZS-108 Phase 1/2 data on refractory bladder and prostate or Perifosine Phase III X-PECT interim data will be released.

(PRWeb May 26, 2011)

Read the full story at http://www.prweb.com/releases/2011/5/prweb8488921.htm

TooNiceStocks Initiates Coverage on IntelGenx Corporation - Troubled Past Potential Bright Future

Mon, 16 May 2011 12:00:00 GMT

TooNiceStocks presents its analysis on IntelGenx Corporation and its lead product CPI-300 with indications for MDD, major depressive disorder. Since the complete response letter from the FDA in February of 2010 for CPI-300, IntelGenx has been an afterthought in the biotech community. However, with the recent events and a new drug application imminent, TooNiceStocks believes IntelGenx might be back on SmallCap & Microcap Investor's radars once again.

(PRWeb May 16, 2011)

Read the full story at http://www.prweb.com/releases/2011/5/prweb8256358.htm

TooNiceStocks Initiates Coverage on Advaxis Inc. Near Term Catalyst a Glimpse to Longer Term Potential

Mon, 02 May 2011 12:30:00 GMT

Advaxis Incorporated, a development stage biotechnology company, is poised for a major advancement if their Phase II cervical cancer vaccine data reflects the same optimistic survival data from prior Phase I data.

(PRWeb May 02, 2011)

Read the full story at http://www.prweb.com/releases/2011/5/prweb8363143.htm

TooNiceStocks Initiates Coverage on Talon Therapeutics Inc. Near Term Catalyst Long Term Potential

Wed, 27 Apr 2011 13:00:00 GMT

TooNiceStocks research has found that Talon Therapeutics is poised for major breakthroughs with their patented drug Marqibo. Marqibo is a nanoparticle encapsulated cancer therapeutic. This unique technology enhances efficacy while reducing toxicity.

(PRWeb April 27, 2011)

Read the full story at http://www.prweb.com/releases/2011/4/prweb8328289.htm

TooNiceStocks Initiates Coverage on Acura Pharmaceuticals Inc. Pending June 17th, 2011 FDA Decision with Elevated Interest

Tue, 05 Apr 2011 13:00:00 GMT

TooNiceStocks research has uncovered a near term catalyst for Acura Pharmaceuticals, Inc. On February 14th, 2011, the FDA accepted the NDA for Acura’s lead product, Acurox. The drug was granted a priority review with a PDUFA (Prescription Drug User Fee Act) date of June 17th, 2011.

(PRWeb April 05, 2011)

Read the full story at http://www.prweb.com/releases/2011/4/prweb8269486.htm

TooNiceStocks Initiates Coverage on Genta Incorporated - A Long History for Long Awaited Data due early Q2 of 2011

Tue, 29 Mar 2011 19:00:00 GMT

Genta Incorporated an oncology drug development and commercialization company will release the long awaited AGENDA’s overall survival data during early Q2 2011.

(PRWeb March 29, 2011)

Read the full story at http://www.prweb.com/releases/2011/3/prweb8248131.htm

TooNiceStocks Initiates Coverage on Neoprobe Corporation -- Researching the Near Term Catalyst, Fundamentals and Product Pipeline

Tue, 29 Mar 2011 13:00:00 GMT

Neoprobe Corporation is the only company to optimize radiotracers and gamma detection hardware concurrently, providing tremendous growth opportunity. Neoprobe have been making remarkable strides within their financial and pipeline.

(PRWeb March 29, 2011)

Read the full story at http://www.prweb.com/releases/2011/3/prweb8248113.htm

TooNiceStocks Initiates Coverage on CorMedix Inc. Near Term Catalyst and Recent Institutional Interest

Mon, 28 Mar 2011 21:00:00 GMT

TooNiceStocks research has unearthed a near-term catalyst in CorMedix Inc. in the form of interim data to be revealed in its phase II trial for its lead product, CRMD001 Deferiprone. CRMD001 will be used for the treatment of contrast-induced nephropathy, hereafter CIN. According to company updates for the year of 2010 and 4Q 2010, this preliminary data will be available in 1Q 2011, which is winding down rapidly. Data for the entire trial will be available in 2H 2011. An additional catalyst due out any time is the investigational device exemption approval by the FDA for CorMedix’s other key product, CRMD003 Neutrolin, to prevent catheter related bloodstream infections. This approval would allow CorMedix to initiate its medical device trial for this indication in which the company has already manufactured its first batch and started stability testing.

(PRWeb March 28, 2011)

Read the full story at http://www.prweb.com/releases/2011/3/prweb8245697.htm

TooNiceStocks Initiates Coverage on Corcept Therapeutics Inc. Evaluating the Benefits of Corlux

Tue, 22 Mar 2011 13:05:00 GMT

Corcept Therapeutics (NASDAQ: CORT) released their final Phase 3 data for Corlux in mid-January, concluding a successful clinical trial. The next anticipated milestone is submission of the New Drug Application to the U.S. Food and Drug Administration. Corcept Therapeutics plans to submit, with a priority review (6-months), end of first quarter. The FDA determines within 45 days after submission to grant priority review.

(PRWeb March 22, 2011)

Read the full story at http://www.prweb.com/releases/2011/3/prweb8225993.htm

TooNiceStocks Initiates Coverage on Adeona Pharmaceuticals, Inc. Near Term Catalyst Brewing and Long Term Possibilities

Fri, 18 Mar 2011 21:00:00 GMT

TooNiceStocks research uncovered that Adeona is expected to complete its prescription medical food trial on reaZin for Alzheimer’s disease and mild cognitive impairment by the end March 2011. In addition, on March 3rd, 2011 the company announced as part of a press release, the data would be presented in a poster presentation at the American Academy of Neurology Annual Meeting on April 14, 2011 at the Hawaii Convention Center in Honolulu, Hawaii.

(PRWeb March 18, 2011)

Read the full story at http://www.prweb.com/releases/2011/3/prweb8218383.htm

TooNiceStocks Initiates Coverage on YM BioSciences Inc. Digging Deeper into the Bullish Sentiment and Upcoming Catalyst in Early June 2011

Wed, 16 Mar 2011 12:30:00 GMT

Why YM BioSciences Inc. will continue its uptrend?

(PRWeb March 16, 2011)

Read the full story at http://www.prweb.com/releases/2011/3/prweb8209392.htm

TooNiceStocks Initiates Coverage on Fibrocell Science Inc. Pending June 22, 2011 FDA Decision with Elevated Interest

Mon, 07 Mar 2011 14:00:00 GMT

On January 12, 2011 Fibrocell Science Inc. announced that the U.S. Food & Drug Administration (FDA) has accepted for review the Company’s complete response submission for azficel-T, proposed brand name laViv®, for the treatment of moderate to severe nasolabial folds and wrinkles. The Prescription Drug User Fee Act (PDUFA) date is June 22, 2011. With a pending FDA decision in the short term horizon, will Fibrocell Science Inc. shares continue to see elevated interest? Time to dig deeper into the current facts and possibilities.

(PRWeb March 07, 2011)

Read the full story at http://www.prweb.com/releases/2011/3/prweb8184441.htm

TooNiceStocks Initiates Coverage on Javelin Pharmaceuticals Inc. on Looming Hospira Inc. Buyout

Thu, 27 May 2010 07:00:00 GMT

Javelin Pharmaceuticals Inc. potential buyout is looming next week (June 2) for $2.20 per share. The buyer Hospira Inc. is currently trading on the NYSE at $51 a share. Will Javelin Pharmaceticals Inc. shares continue to rally toward closing date or will retailers bail before then?

(PRWeb May 27, 2010)

Read the full story at http://www.prweb.com/releases/2010/05/prweb4057594.htm

TooNiceStocks Initiates Coverage on Upcoming Crucial FDA Clinical Trial Results for Guided Therapeutics Inc.

Wed, 17 Mar 2010 07:00:00 GMT

TooNiceStocks.com, a premier investment blog that “finds the value in the undervalued” companies has initiated independent research on Guided Therapeutics Inc. Please visit http://www.TooniceStocks.com to view the full world famous due diligence report.

(PRWeb March 17, 2010)

Read the full story at http://www.prweb.com/releases/2010/03/prweb3734434.htm